Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76280
Title:
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
Authors:
Geoerger, B; Vassal, G; Doz, F; O'Quigley, J; Wartelle, M; Watson, Amanda J; Raquin, M-A; Frappaz, D; Chastagner, P; Gentet, J-C; Rubie, H; Couanet, D; Geoffray, A; Djafari, L; Margison, Geoffrey P; Pein, F
Abstract:
Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT). This phase I/II study determined recommended combination doses using the Continual Reassessment Method, toxicities and antitumour activity in paediatric patients, and evaluated MGMT in peripheral blood mononuclear cells (PBMCs) in order to correlate with haematological toxicity. In total, 39 patients with refractory or recurrent solid tumours (median age approximately 13 years; 14 pretreated with high-dose chemotherapy, craniospinal irradiation, or having bone marrow involvement) were treated with cisplatin, followed the next day by oral temozolomide for 5 days every 4 weeks at dose levels 80 mg m(-2)/150 mg m(-2) day(-1), 80/200, and 100/200, respectively. A total of 38 patients receiving 113 cycles (median 2, range 1-7) were evaluable for toxicity. Dose-limiting toxicity was haematological in all but one case. Treatment-related toxicities were thrombocytopenia, neutropenia, nausea-vomiting, asthenia. Hearing loss was experienced in five patients with prior irradiation to the brain stem or posterior fossa. Partial responses were observed in two malignant glioma, one brain stem glioma, and two neuroblastoma. Median MGMT activity in PBMCs decreased after 5 days of temozolomide treatment: low MGMT activity correlated with increased severity of thrombocytopenia. Cisplatin-temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m(-2) cisplatin and 150 mg m(-2) x 5 temozolomide in heavily treated, and 200 mg m(-2) x 5 temozolomide in less-heavily pretreated children.
Affiliation:
Department of Pediatrics, Institut Gustave Roussy, Villejuif, France. geoerger@igr.fr
Citation:
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. 2005, 93 (5):529-37 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
5-Sep-2005
URI:
http://hdl.handle.net/10541/76280
DOI:
10.1038/sj.bjc.6602740
PubMed ID:
16136028
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGeoerger, B-
dc.contributor.authorVassal, G-
dc.contributor.authorDoz, F-
dc.contributor.authorO'Quigley, J-
dc.contributor.authorWartelle, M-
dc.contributor.authorWatson, Amanda J-
dc.contributor.authorRaquin, M-A-
dc.contributor.authorFrappaz, D-
dc.contributor.authorChastagner, P-
dc.contributor.authorGentet, J-C-
dc.contributor.authorRubie, H-
dc.contributor.authorCouanet, D-
dc.contributor.authorGeoffray, A-
dc.contributor.authorDjafari, L-
dc.contributor.authorMargison, Geoffrey P-
dc.contributor.authorPein, F-
dc.date.accessioned2009-08-04T17:20:59Z-
dc.date.available2009-08-04T17:20:59Z-
dc.date.issued2005-09-05-
dc.identifier.citationDose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. 2005, 93 (5):529-37 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid16136028-
dc.identifier.doi10.1038/sj.bjc.6602740-
dc.identifier.urihttp://hdl.handle.net/10541/76280-
dc.description.abstractCisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT). This phase I/II study determined recommended combination doses using the Continual Reassessment Method, toxicities and antitumour activity in paediatric patients, and evaluated MGMT in peripheral blood mononuclear cells (PBMCs) in order to correlate with haematological toxicity. In total, 39 patients with refractory or recurrent solid tumours (median age approximately 13 years; 14 pretreated with high-dose chemotherapy, craniospinal irradiation, or having bone marrow involvement) were treated with cisplatin, followed the next day by oral temozolomide for 5 days every 4 weeks at dose levels 80 mg m(-2)/150 mg m(-2) day(-1), 80/200, and 100/200, respectively. A total of 38 patients receiving 113 cycles (median 2, range 1-7) were evaluable for toxicity. Dose-limiting toxicity was haematological in all but one case. Treatment-related toxicities were thrombocytopenia, neutropenia, nausea-vomiting, asthenia. Hearing loss was experienced in five patients with prior irradiation to the brain stem or posterior fossa. Partial responses were observed in two malignant glioma, one brain stem glioma, and two neuroblastoma. Median MGMT activity in PBMCs decreased after 5 days of temozolomide treatment: low MGMT activity correlated with increased severity of thrombocytopenia. Cisplatin-temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m(-2) cisplatin and 150 mg m(-2) x 5 temozolomide in heavily treated, and 200 mg m(-2) x 5 temozolomide in less-heavily pretreated children.en
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectCancer Stagingen
dc.subjectCanceren
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshCisplatin-
dc.subject.meshDacarbazine-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshMale-
dc.subject.meshMaximum Tolerated Dose-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeoplasm Staging-
dc.subject.meshNeoplasms-
dc.subject.meshO(6)-Methylguanine-DNA Methyltransferase-
dc.subject.meshSalvage Therapy-
dc.subject.meshTreatment Outcome-
dc.titleDose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pediatrics, Institut Gustave Roussy, Villejuif, France. geoerger@igr.fren
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.